SCHEMBL13429205

SCHEMBL13429205

CN(C)CCCNC(=O)c1cccc(-c2cccc(Oc3cc(=O)[nH]c4ccccc34)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
HSD17B10 Q99714 2/20 0.56
FYN P06241 2/20 0.47
TLR9 Q9NR96 2/20 0.46
TLR8 Q9NR97 2/20 0.46
TLR7 Q9NYK1 2/20 0.46
PARP1 P09874 1/20 0.45
METAP2 P50579 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
CHUK O15111 1/20 0.44
INSR P06213 1/20 0.44
MAPK8 P45983 1/20 0.44
CAMKK2 Q96RR4 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MITF O75030 1/20 0.44
POLB P06746 1/20 0.44
RAD52 P43351 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429223 0.95 FYN (0.49) KDM4EALDH1A1HPGDHSD17B10FYN
SCHEMBL13429221 0.88 JAK2 (0.48) KDM4EALDH1A1HPGDHSD17B10FYN
SCHEMBL13429222 0.82 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10TLR8
SCHEMBL13429224 0.82 MAPK1 (0.40) KDM4EALDH1A1HPGDTLR9TLR8
SCHEMBL3216980 0.80 ATM (0.49) MEN1KMT2AIGF1R
SCHEMBL13429299 0.79 MEN1 (0.43) KDM4EALDH1A1HPGDHSD17B10TLR9
SCHEMBL3209472 0.76 TLR9 (0.49) FYNTLR9TLR8TLR7METAP2
SCHEMBL13429161 0.74 HPGD (0.54) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL3227602 0.73 KMT2A (0.43) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL13429218 0.73 KDM4E (0.44) KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA KDM4E 728/4885ALDH1A1 2884/4885HPGD 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.